Scarica l'app Stockscreener
233.80
6.09%
-15.15
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Precedente Chiudi:
$248.95
Aprire:
$248.32
Volume 24 ore:
804.50K
Relative Volume:
0.89
Capitalizzazione di mercato:
$12.03B
Reddito:
$708.24M
Utile/perdita netta:
$-188.30M
Rapporto P/E:
-62.53
EPS:
-3.7392
Flusso di cassa netto:
$-70.99M
1 W Prestazione:
-4.30%
1M Prestazione:
-5.09%
6M Prestazione:
+38.03%
1 anno Prestazione:
+111.14%
Intervallo 1D:
$230.14
$249.11
Intervallo di 1 settimana:
$230.14
$252.60
Portata 52W:
$96.09
$260.19
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Nome
Axsome Therapeutics Inc
Settore
Industria
Telefono
(212) 332-3241
Indirizzo
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
233.80 | 12.03B | 708.24M | -188.30M | -70.99M | -3.7392 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-01 | Iniziato | B. Riley Securities | Buy |
| 2025-09-03 | Ripresa | Wells Fargo | Overweight |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-06-03 | Iniziato | Oppenheimer | Outperform |
| 2025-04-07 | Iniziato | Jefferies | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-12-31 | Reiterato | Mizuho | Outperform |
| 2024-09-03 | Iniziato | Wells Fargo | Overweight |
| 2024-08-06 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-04-29 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2024-01-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-08-08 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Iniziato | Piper Sandler | Neutral |
| 2022-11-01 | Iniziato | Loop Capital | Buy |
| 2022-09-07 | Ripresa | Mizuho | Buy |
| 2021-08-10 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Iniziato | Berenberg | Buy |
| 2021-01-08 | Iniziato | Jefferies | Buy |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-09-29 | Iniziato | BofA Securities | Underperform |
| 2020-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2020-04-28 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-14 | Iniziato | Cowen | Outperform |
| 2019-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-17 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-16 | Reiterato | Guggenheim | Buy |
| 2019-10-16 | Iniziato | Guggenheim | Buy |
| 2019-09-18 | Iniziato | William Blair | Outperform |
| 2019-05-28 | Iniziato | SunTrust | Buy |
| 2019-05-23 | Reiterato | H.C. Wainwright | Buy |
| 2019-04-08 | Iniziato | SVB Leerink | Outperform |
| 2019-03-15 | Reiterato | H.C. Wainwright | Buy |
| 2016-10-03 | Ripresa | Brean Capital | Buy |
| 2015-12-15 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-12-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
AXSM Stock Is Rising Today After Wall Street’s Positive Stance Despite Mixed Q1 – What's Behind The Optimism? - Stocktwits
AXSM Stock In Spotlight Ahead Of Key FDA Verdict On Alzheimer’s Drug This Week - Stocktwits
Why Axsome Therapeutics (AXSM) Stock Is Down Today - Moomoo
Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock - Stocktwits
Axsome Therapeutics (AXSM) Stock Looks Pricey On Sales Yet Fair On Value - Yahoo Finance
How Investors May Respond To Axsome Therapeutics (AXSM) Advancing Solriamfetol Into Phase 3 Pediatric ADHD Trials - Yahoo Finance
Axsome Therapeutics (AXSM) Following FOCUS 2 Dosing Is The ADHD Upside Already Priced In - Yahoo Finance
Axsome Therapeutics, Inc. $AXSM Shares Sold by Granite Investment Partners LLC - MarketBeat
Better Growth Buy: Axsome vs Revolution Medicines - The Motley Fool
Axsome Therapeutics (AXSM) Could Be 11% Undervalued Following Its Pediatric ADHD Trial Start - simplywall.st
Burney Co. Invests $1.63 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Is Axsome Therapeutics, Inc. (AXSM) Among the Best Under-the-Radar Stocks to Invest In? - Insider Monkey
Axsome Begins Phase III Study on Solriamfetol for ADHD in Children - Yahoo Finance
AXSM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $290 - GuruFocus
Axsome Therapeutics' (AXSM) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Axsome stock rating on ADHD trials - Investing.com
H.C. Wainwright reiterates Axsome stock rating on ADHD trials By Investing.com - Investing.com Canada
RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $304 - Moomoo
Analysts Have Conflicting Sentiments on These Healthcare Companies: HUTCHMED (HCM), Axsome Therapeutics (AXSM) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $290 - Moomoo
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $310 - Moomoo
Axsome Therapeutics, Exelixis, Incyte Among 20 New Stocks On IBD's Premier Watchlists - Investor's Business Daily
Axsome Therapeutics doses first pediatric patient in Phase 3 ADHD study - grafa.com
RBC Capital Adjusts Axsome Therapeutics Price Target to $304 From $302, Maintains Outperform Rating - Moomoo
Axsome doses first patient in pediatric ADHD trial By Investing.com - Investing.com South Africa
Axsome Therapeutics Doses First Patient in Trial of Potential ADHD Drug - marketscreener.com
Axsome doses first patient in pediatric ADHD trial - Investing.com
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD) - The Manila Times
Axsome starts Phase 3 ADHD trial in children, enrolling 468 patients - Stock Titan
Sleep Apnea Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Apnimed, Eli Lilly, Incannex Healthcare, Axsome Therapeutics, Jazz Pharma, Bioprojet - Barchart.com
These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More - The Motley Fool
Axsome Therapeutics (AXSM) Stock Analysis: Unveiling a 13% Potential Upside Amid Robust Revenue Growth - DirectorsTalk Interviews
Responsive Playbooks and the AXSM Inflection - Stock Traders Daily
The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Phase 3 ADHD Trial And Index Moves - simplywall.st
HB Wealth Management LLC Grows Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
ETFs Investing in Axsome Therapeutics, Inc. Stocks - TradingView
SG Americas Securities LLC Has $1.25 Million Stock Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
If You Invested $1,000 in Axsome Therapeut (AXSM) - Stock Titan
Is Axsome Therapeutics Stock a Millionaire Maker? Here's What the Numbers Say. - The Motley Fool
Axsome Therapeutics(AXSM.US) 10% Shareholder Sells US$11.93 Million in Common Stock - Moomoo
Axsome therapeutics CEO Herriot Tabuteau sells $11.9 million in shares - Investing.com UK
Form 4 Axsome Therapeutics Inc For: 1 July By Investing.com - Investing.com Canada
Axsome therapeutics CEO Herriot Tabuteau sells $11.9 million in shares By Investing.com - Investing.com South Africa
Axsome Therapeutics (AXSM) CEO sells 49,666 exercised shares under 10b5-1 plan - Stock Titan
Form 144 Axsome Therapeutics For: 1 July By Investing.com - Investing.com Canada
Form 144 | Axsome Therapeutics(AXSM.US) Officer Proposes to Sell 11.95 Million in Common Stocks - Moomoo
49,666-share sale notice for AXSM (NASDAQ: AXSM) via cashless exercise - Stock Titan
Why Axsome Stock Has Doubled In Nine Months - Yahoo! Finance Canada
Pictet Asset Management Holding SA Sells 20,080 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Sleep Apnea Market Expected to Experience Accelerated Growth and Market Evolution by 2034 – DelveInsight | Apnimed, Eli Lilly, Incannex Healthcare, Axsome Therapeutics, Jazz Pharma, Bioprojet - Barchart.com
Axsome Therapeutics, Inc.(NasdaqGM: AXSM) dropped from Russell 2000 Index - marketscreener.com
Axsome Therapeutics Inc Azioni (AXSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Axsome Therapeutics Inc Azioni (AXSM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| TABUTEAU HERRIOT | Chief Executive Officer |
Jul 01 '26 |
Sale |
240.25 |
49,666 |
11,932,256 |
7,229 |
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):